2[1]Plesner T, Behrendt N, Ploug M. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor,u-PAR. Stem Cells, 1997,15(6) :398 ～ 408.
3[2]Pepper MS. Role of the matrix metalloproteinase and plasminogen activatorplasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol, 2001,21(7):1104～ 1117.
4[3]Ploug M, Plesner T, Ronne E, et al. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. Blood, 1992,79(6): 1447 ～ 1455.
5[4]Ronne E, Pappot H, Groodahl-Hansen J, et al. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol, 1995,89(3) :576 ～ 581.
6[5]Ploug M, Eriksen J, Plesner T, et al. Soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted fron peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria. Eur J Biochem, 1992,208(2) :397 ～ 404.
7[6]Ninomiya H, Hasegawa Y, Nagasawa T, et al. Excess soluble urokinase-type plasminogen activator receptor in the plasma of patients with paroxysmal nocturnal hemoglobinuria inbibits cell-associated fibrinolytic activity. Int J Hematol, 1997,65(3) :285 ～ 291.
8[8]Ray JG, Burows RF, Ginsberg JS, et al. Paroxysmal nocturnal hemoglobinuria and the risk of venous thrombosis: reviewand recommendations for management of the pregnant and nonpregnant patient. Hanemostasis, 2000, 30(3):103 ～ 117.
9[9]Socie G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of laematology, 1996,348(9027) :573 ～ 577.
10Rosse WF, Ware RE. The molecular basis of paroxysmal nocturnal hemoglobinuria[J]. Blood, 1995, 86:3277-3286.
